Be ready for the possible transition from RRMS to SPMS by understanding new symptoms, treatment options, and what to discuss ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...

A recent study reveals that over one-third of individuals with relapsing-remitting multiple sclerosis (MS) do not fully recover from relapses, highlighting critical recovery factors. MS is one of the ...

Leading U.S. stem cell banking and cellular therapeutic manufacturer Hope Biosciences announces the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) ...

For people living with multiple sclerosis (MS), the search for effective treatment options can feel like a never-ending journey. While disease-modifying therapies (DMTs) have improved outcomes for ...

Ublituximab demonstrates sustained efficacy and a favorable safety profile through 6 years of treatment for relapsing MS.

Restricted coverage of medications for relapsing-remitting multiple sclerosis (MS) was associated with a higher risk for relapse, a new study showed. Patients with MS enrolled in Medicare Advantage ...